Impact of Health Lifestyle on Body Weight
1 other identifier
observational
190
1 country
1
Brief Summary
Pharmacotherapy becomes an important and effective approach to improve body weight. However, it still remains unclear how to manage potential fluctuation after its cessation. Lifestyle change is the foundation and included as a part of clinical routine in real-world, therefore, we plan to conduct a prospective observational study to assess the impact of health lifestyle along with its compliance on body weight in Chinese people who live with obesity or overweight and are off-pharmacotherapy trial. The aim of this study is to examine the impact of health lifestyle along with its compliance on body weight related parameters in 6 months at 3 monthly intervals from treatment. In addition, body weight related results will be described.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 15, 2022
CompletedFirst Submitted
Initial submission to the registry
November 2, 2022
CompletedFirst Posted
Study publicly available on registry
November 8, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2023
CompletedNovember 28, 2022
November 1, 2022
10 months
November 2, 2022
November 21, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Fluctuation in body weight
To examine the weight fluctuation by health lifestyle compliance from baseline
6 months
Secondary Outcomes (3)
Change of blood lipids
6 months
Change of blood glucose levels
6 months
Change of blood pressure
6 months
Eligibility Criteria
All subjects who completed a pharmacotherapy trial will be recruited and who consent to this follow-up study.
You may qualify if:
- All patients who completed a pharmacotherapy trial
- Those who consent to this FU study
You may not qualify if:
- Those who do not consent to this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Xiaoying Li
Shanghai, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 2, 2022
First Posted
November 8, 2022
Study Start
September 15, 2022
Primary Completion
June 30, 2023
Study Completion
September 30, 2023
Last Updated
November 28, 2022
Record last verified: 2022-11
Data Sharing
- IPD Sharing
- Will not share